Dr. Peter Kaspar Joins First Light Diagnostics Board of Directors

February 6, 2019

CHELMSFORD, Mass. (Feb. 6, 2019) – First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the addition of Dr. Peter Kaspar to the company’s board of directors effective January 1, 2019.

“Peter is one of the most respected executives in life sciences and diagnostics,” said David Macdonald, CEO of First Light Diagnostics. “His unique experience across strategy, business development and R&D management will provide valuable guidance as we move into the next phase of our test menu development.”

Dr. Kaspar has been a member of the executive committee of bioMérieux, where he was responsible for the Molecular Diagnostics Unit, Global Research & Development and subsequently the Microbiology Unit. Across his 40 years of experience, Dr. Kaspar has held executive roles with global organizations. From his former role in the FIND Diagnostics management team, a Geneva-based non-profit organization, he developed a deep understanding of the public health sector. He holds a Ph.D. in biochemistry from the University of Muenster in Germany.

“I am excited to join the First Light Diagnostics board at such an important phase in the company’s evolution,“ said Dr. Peter Kaspar. “First Light’s use of technology to address the challenge of detecting infections and determining appropriate antibiotic therapy will have a tremendous positive impact on patient outcomes and lower healthcare cost.”
About First Light Diagnostics
First Light Diagnostics is developing and preparing to commercialize, innovative diagnostic products for rapid, sensitive and cost-saving detection of life-threatening infections, and for combating the spread of antibiotic resistance. Don Straus is the company’s Founder and primary inventor of the company’s core scientific technology. Based on its proprietary MultiPath detection technology, First Light’s products combine the clinical performance of the most advanced commercial laboratory tests with speed, cost-effectiveness, and ease-of-use. The tests rapidly detect infections, identify infectious agents, and determine effective targeted antibiotic therapy. This will improve patient outcomes, reduce healthcare costs, and prevent inappropriate use of powerful antibiotics. To learn more, please visit www.firstlightdx.com.

Read the full press release here.